Patents by Inventor Harald Hach
Harald Hach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075026Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: ApplicationFiled: February 8, 2023Publication date: March 7, 2024Applicant: AbbVie Inc.Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
-
Patent number: 11246866Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: GrantFiled: October 16, 2019Date of Patent: February 15, 2022Assignee: AbbVie Inc.Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
-
Publication number: 20200282004Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: ApplicationFiled: October 16, 2019Publication date: September 10, 2020Applicant: AbbVie Inc.Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
-
Publication number: 20200253968Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: ApplicationFiled: October 16, 2019Publication date: August 13, 2020Applicant: AbbVie Inc.Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
-
Publication number: 20190216882Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: ApplicationFiled: December 20, 2018Publication date: July 18, 2019Applicant: AbbVie Inc.Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
-
Publication number: 20160375017Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: ApplicationFiled: July 18, 2016Publication date: December 29, 2016Applicant: AbbVie Inc.Inventors: Katharina Asmus, Yi Gao, Colleen Garrett, Harald Hach, Adivaraha Jayasankar, Kyeremateng Samuel, Ute Lander, Thomas Mueller, Marius Naris, Constanze Obermiller, Regina Reul, Katrin Schneider, Nancy Sever, Michael Simon, Benedikt Steitz, Ping Tong, Ulrich Westedt, Donghua Zhu
-
Publication number: 20160375087Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.Type: ApplicationFiled: June 24, 2016Publication date: December 29, 2016Applicant: AbbVie Inc.Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
-
Patent number: 8841303Abstract: The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.Type: GrantFiled: November 8, 2007Date of Patent: September 23, 2014Assignees: Abbvie Deutschland GmbH & Co. KG, Novartis AGInventors: Jörg Breitenbach, Norbert Steiger, Harald Hach, Ulrich Westedt, Martin Knobloch, Ralf Altenburger, Nicoletta Loggia, Jörg Ogorka
-
Patent number: 8337733Abstract: A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1:1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.Type: GrantFiled: August 14, 2008Date of Patent: December 25, 2012Assignee: Abbott GmbH & Co. KGInventors: Ulrich Westedt, Jörg Rosenberg, Martin Knobloch, Norbert Steiger, Harald Hach
-
Publication number: 20120001361Abstract: A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1:1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.Type: ApplicationFiled: August 14, 2008Publication date: January 5, 2012Applicant: ABBOTT GMBH & CO. KGInventors: Ulrich Westedt, Jörg Rosenberg, Martin Knobloch, Norbert Steiger, Harald Hach
-
Publication number: 20100240672Abstract: The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.Type: ApplicationFiled: November 8, 2004Publication date: September 23, 2010Applicants: ABBOTT GMBH & CO. KG, NOVARTIS AGInventors: Jorg Breitenbach, Norbert Steiger, Harald Hach, Ulrich Westedt, Martin Knobloch, Ralf Altenburger, Nicoletta Loggia, Jörg Ogorka
-
Publication number: 20090274731Abstract: A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described.Type: ApplicationFiled: May 23, 2007Publication date: November 5, 2009Applicant: ABBOTT GMBH & CO. KGInventors: Jörg Rosenberg, Harald Hach, Ulrich Westedt, Martin Knobloch, Jörg Breitenbach
-
Publication number: 20090050262Abstract: Disclosed is a method for producing dosing molds, according to which two separating films (7) are contacted with each other in a defined area, an active substance-containing melt is introduced between the separating films (7) such that a pocket for receiving a portion of the melt is embodied in at least one of the separating films, and the separating films (7) are separated from each other in order to eject the portion. Preferably, a method is disclosed in which the separating films (7) are contacted with each other in the gap of two molding rolls (2, 3) which rotate in opposite directions and are provided with opposite recesses (4, 5) on the surface thereof, and into which the separating films (7) can be pressed when the active substance-containing melt is introduced so as to form pockets. The separating films (7) make it possible to avoid a direct contact between the melt and the rolls (4,5) and thus prevent the melt from adhering to the roll (2, 3).Type: ApplicationFiled: February 17, 2006Publication date: February 26, 2009Inventors: Jorg Rosenberg, Norbert Steiger, Harald Hach, Jorg Breitenbach
-
Patent number: 6726929Abstract: A pharmaceutical mixture comprising a profen is described which has a profen content of over 85% and contains up to 1% of a nonionic surfactant having an HLB of ≧9 and also a customary disintegrant and a lubricant and optionally a microcrystalline cellulose.Type: GrantFiled: June 14, 2001Date of Patent: April 27, 2004Assignee: BASF AktiengesellschaftInventors: Heinz Einig, Harald Hach, Richard C. Thompson, Raymond Eason, Bernd W. Müller
-
Patent number: 6251945Abstract: A pharmaceutical mixture comprising a profen and one or more additional active compounds is described which has a total active compound content of over 85% and contains up to 1%, based on the content of the profen, of a nonionic surfactant having an HLB of ≧9 and a customary disintegrant and a lubricant.Type: GrantFiled: January 14, 1999Date of Patent: June 26, 2001Assignee: Knoll AktiengesellschaftInventors: Heinz Einig, Harald Hach, Raymond Eason, Bernd W. Müller, Richard C. Thompson